Literature DB >> 25135842

Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic.

Jamie P Morano1, Alexei Zelenev, Andrea Lombard, Ruthanne Marcus, Britton A Gibson, Frederick L Altice.   

Abstract

Despite new Hepatitis C virus (HCV) therapeutic advances, challenges remain for HCV testing and linking patients to care. A point-of-care (POC) HCV antibody testing strategy was compared to traditional serological testing to determine patient preferences for type of testing and linkage to treatment in an innovative mobile medical clinic (MMC). From 2012 to 2013, all 1,345 MMC clients in New Haven, CT underwent a routine health assessment, including for HCV. Based on patient preferences, clients could select between standard phlebotomy or POC HCV testing, with results available in approximately 1 week versus 20 min, respectively. Outcomes included: (1) accepting HCV testing; (2) preference for rapid POC HCV testing; and (3) linkage to HCV care. All clients with reactive test results were referred to a HCV specialty clinic. Among the 438 (32.6 %) clients accepting HCV testing, HCV prevalence was 6.2 % (N = 27), and 209 (47.7 %) preferred POC testing. Significant correlates of accepting HCV testing was lower for the "baby boomer" generation (AOR 0.67; 95 % CI 0.46-0.97) and white race (AOR 0.55; 95 % CI 0.36-0.78) and higher for having had a prior STI diagnosis (AOR 5.03; 95 % CI 1.76-14.26), prior injection drug use (AOR 2.21; 95 % CI 1.12-4.46), and being US-born (AOR 1.76; 95 % CI 1.25-2.46). Those diagnosed with HCV and preferring POC testing (N = 16) were significantly more likely than those choosing standard testing (N = 11) to be linked to HCV care within 30 days (93.8 vs. 18.2 %; p < 0.0001). HCV testing is feasible in MMCs. While patients equally preferred POC and standard HCV testing strategies, HCV-infected patients choosing POC testing were significantly more likely to be linked to HCV treatment. Important differences in risk and background were associated with type of HCV testing strategy selected. HCV testing strategies should be balanced based on costs, convenience, and ability to link to HCV treatment.

Entities:  

Mesh:

Year:  2014        PMID: 25135842      PMCID: PMC8317466          DOI: 10.1007/s10900-014-9932-9

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  56 in total

1.  HIV in prison in low income countries.

Authors:  Bléhoué Angora; Jeanne d'Arc Assemien; Arnaud Laurent; Vincent Febro; Madiarra Coulibaly-Offia; Jean-Marie Masumbuko; Rigobert A Kakou; Virginie E Traore; Serge Eholie; Gilles Brucker; Denis Lacoste; Gilles Raguin
Journal:  AIDS       Date:  2011-06-01       Impact factor: 4.177

2.  The mobile unit: a new approach in mental health.

Authors:  P Ruiz; W Vazquez; K Vazquez
Journal:  Community Ment Health J       Date:  1973

3.  Immigrant women's experiences of receiving care in a mobile health clinic.

Authors:  Sepali Guruge; Joanne Hunter; Keegan Barker; Mary Jane McNally; Lilian Magalhães
Journal:  J Adv Nurs       Date:  2010-02       Impact factor: 3.187

4.  Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention.

Authors:  Kimberly Page; Meghan D Morris; Judith A Hahn; Lisa Maher; Maria Prins
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

5.  Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-05-06       Impact factor: 17.586

6.  Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial.

Authors:  Frederick L Altice; Duncan Smith-Rohrberg Maru; R Douglas Bruce; Sandra A Springer; Gerald H Friedland
Journal:  Clin Infect Dis       Date:  2007-08-13       Impact factor: 9.079

7.  Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening.

Authors:  Ryan K Schwarz; R Douglas Bruce; Samuel A Ball; Maua Herme; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

8.  Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment.

Authors:  Sandra Ann Springer; Shu Chen; Frederick L Altice
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

9.  Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study.

Authors:  Julie Bruneau; Geng Zang; Michal Abrahamowicz; Didier Jutras-Aswad; Mark Daniel; Elise Roy
Journal:  Clin Infect Dis       Date:  2013-12-20       Impact factor: 9.079

Review 10.  Patients' preferences within randomised trials: systematic review and patient level meta-analysis.

Authors: 
Journal:  BMJ       Date:  2008-10-31
View more
  33 in total

Review 1.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

2.  Hepatitis B screening in an argentine ED: Increasing vaccination in a resource-limited setting.

Authors:  James S Ford; Leonardo G Marianelli; Natalia Frassone; Jose D Debes
Journal:  Am J Emerg Med       Date:  2019-07-18       Impact factor: 2.469

Review 3.  Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Authors:  Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely
Journal:  Liver Int       Date:  2018-09-22       Impact factor: 5.828

Review 4.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Authors:  Jaimie P Meyer; Yavar Moghimi; Ruthanne Marcus; Joseph K Lim; Alain H Litwin; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2015-05-17

5.  An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.

Authors:  David C Perlman; Ashly E Jordan; Anneli Uuskula; Duong Thi Huong; Carmen L Masson; Bruce R Schackman; Don C Des Jarlais
Journal:  Int J Drug Policy       Date:  2015-04-27

Review 6.  HIV/HCV Co-infection: Burden of Disease and Care Strategies in Appalachia.

Authors:  Jonathan P Moorman; Matthew R Krolikowski; Stephanie M Mathis; Robert P Pack
Journal:  Curr HIV/AIDS Rep       Date:  2018-08       Impact factor: 5.071

7.  Economic Comparison of Serologic and Molecular Screening Strategies for Hepatitis C Virus.

Authors:  Sammy Saab; Timothy Ahn; Terina McDaniel; Beshoy Yanny; Myron J Tong
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-08

8.  Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study.

Authors:  Alain H Litwin; John Jost; Katherine Wagner; Moonseong Heo; Alison Karasz; Judith Feinberg; Arthur Y Kim; Paula J Lum; Shruti H Mehta; Lynn E Taylor; Judith I Tsui; Irene Pericot-Valverde; Kimberly Page
Journal:  Contemp Clin Trials       Date:  2019-10-24       Impact factor: 2.226

9.  Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

Authors:  Jason Grebely; Julie Bruneau; Jeffrey V Lazarus; Olav Dalgard; Philip Bruggmann; Carla Treloar; Matthew Hickman; Margaret Hellard; Teri Roberts; Levinia Crooks; Håvard Midgard; Sarah Larney; Louisa Degenhardt; Hannu Alho; Jude Byrne; John F Dillon; Jordan J Feld; Graham Foster; David Goldberg; Andrew R Lloyd; Jens Reimer; Geert Robaeys; Marta Torrens; Nat Wright; Icro Maremmani; Brianna L Norton; Alain H Litwin; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2017-07-03

10.  Point-of-care hepatitis C screening with direct access referral to improve linkage to care among halfway house residents: a pilot randomised study.

Authors:  John Chen Hsiang; Pream Sinnaswami; Mui Yok Lee; Meng Meng Zhang; Kwang Ee Quek; Keng Hwee Tan; Yew Meng Wong; Prem Harichander Thurairajah
Journal:  Singapore Med J       Date:  2020-07-30       Impact factor: 3.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.